Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.

Wells Fargo analyst Mohit Bansal maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research Report) and Apellis ...

Despite this positive financial performance, the company’s stock experienced a decline in pre-market trading. DA Davidson recently adjusted its financial outlook for Vertex, lowering the price target ...

(Adds company news items, futures) March 23 (Reuters) - Britain's FTSE 100 futures FFIc1 were flat ahead of the cash market open... March 23 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening ...

(Reuters) -UnitedHealth Group’s pharmacy benefit manager, Optum Rx, said on Wednesday it would ease requirements to get insurance authorization when renewing prescriptions on about 80 drugs ...

Vertex Growth Fund and Anicut Equity Continuum Fund, reaffirming strong investor confidence in the company's future. Pilgrim's valuation has surged to approximately ₹3,000 crore pre-money, reflecting ...

Pilgrim, a leading Indian clean beauty brand, has secured Rs 200 crore in a new funding round, valuing the company at approximately Rs 3,000 crore pre-money ... investors Narotam Sekhsaria Family ...

Existing investors included Narotam Sekhsaria Family Office (NSFO), Vertex Ventures SEA, Sattva Family Office, and Mirabilis Investment Trust, while new investors joining the company’s cap table ...

On March 14, 2025, at the International Criminal Court in The Hague, Netherlands, members of Pre-Trial Chamber I—Presiding Judge Iulia Antoanella Motoc, Judge Reine Adélaïde Sophie Alapini ...

Everybody needs a calculator. Because of this, there have been many calculators through the years, and they’re actually pretty easy to find. Most people use them to figure out stuff like how ...

Casgevy, a sickle cell treatment developed by Vertex and CRISPR Therapeutics, became the first CRISPR therapy approved by the US Food and Drug Administration (FDA) in December 2023. With AWS on ...